semaglutide adolescent obesity trial 2022 ObesityWeek 2022: Shows Promise in Adolescents Wegovy approved to help teens

Semaglutide's 7-day half-life means that approximately 87% of drug exposure clears within 4 half-lives (28 days) [5]

Safety and Tolerability Results Phase 1 trials demonstrated that Retatrutide was generally well-tolerated across the tested dose range

Gastrointestinal side effects associated with semaglutide typically occur more frequently during the initial weeks of treatment or following dose escalation

F.de OliveiraP

The NCA solution was added to the initiator solution after the completion of dissolution

With integrated metabolic approaches gaining traction, primary care providers, endocrinologists, and diabetes educators will need to revise protocols and adopt longer-term management strategies